Cargando…

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes

Detalles Bibliográficos
Autores principales: Hyak, Jonathan M., Huang, Ying, Rogers, Kerry A., Bhat, Seema A., Grever, Michael R., Byrd, John C., Kittai, Adam S., Jones, Dan, Miller, Cecelia R., Woyach, Jennifer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631640/
https://www.ncbi.nlm.nih.gov/pubmed/35834733
http://dx.doi.org/10.1182/bloodadvances.2022007708
_version_ 1784823857471815680
author Hyak, Jonathan M.
Huang, Ying
Rogers, Kerry A.
Bhat, Seema A.
Grever, Michael R.
Byrd, John C.
Kittai, Adam S.
Jones, Dan
Miller, Cecelia R.
Woyach, Jennifer A.
author_facet Hyak, Jonathan M.
Huang, Ying
Rogers, Kerry A.
Bhat, Seema A.
Grever, Michael R.
Byrd, John C.
Kittai, Adam S.
Jones, Dan
Miller, Cecelia R.
Woyach, Jennifer A.
author_sort Hyak, Jonathan M.
collection PubMed
description
format Online
Article
Text
id pubmed-9631640
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-96316402022-11-04 Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes Hyak, Jonathan M. Huang, Ying Rogers, Kerry A. Bhat, Seema A. Grever, Michael R. Byrd, John C. Kittai, Adam S. Jones, Dan Miller, Cecelia R. Woyach, Jennifer A. Blood Adv Research Letter American Society of Hematology 2022-09-01 /pmc/articles/PMC9631640/ /pubmed/35834733 http://dx.doi.org/10.1182/bloodadvances.2022007708 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
spellingShingle Research Letter
Hyak, Jonathan M.
Huang, Ying
Rogers, Kerry A.
Bhat, Seema A.
Grever, Michael R.
Byrd, John C.
Kittai, Adam S.
Jones, Dan
Miller, Cecelia R.
Woyach, Jennifer A.
Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
title Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
title_full Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
title_fullStr Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
title_full_unstemmed Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
title_short Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
title_sort combined bcl2 and btk inhibition in cll demonstrates efficacy after monotherapy with both classes
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631640/
https://www.ncbi.nlm.nih.gov/pubmed/35834733
http://dx.doi.org/10.1182/bloodadvances.2022007708
work_keys_str_mv AT hyakjonathanm combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses
AT huangying combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses
AT rogerskerrya combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses
AT bhatseemaa combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses
AT grevermichaelr combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses
AT byrdjohnc combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses
AT kittaiadams combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses
AT jonesdan combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses
AT millerceceliar combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses
AT woyachjennifera combinedbcl2andbtkinhibitioninclldemonstratesefficacyaftermonotherapywithbothclasses